IPO Roundup: 3 companies _ DBV Technologies, Proteon and Anchor BanCorp _ rise in their debut

Markets Associated Press

Shares rose of the three companies that began trading on Wednesday.

Continue Reading Below

Two of the companies are drug and treatment developers, while the other is a Midwest bank holding company.

Here's how each did in their stock market debut:

DBV TECHNOLOGIES S.A.

The French company is developing a patch that helps manage peanut allergies. It raised about $92.6 million after offering 4.3 million American depositary shares at $21.64 each. The company plans to use the money raised to complete another clinical trial of its peanut allergy patch and to test patches for other allergies. Shares of the company, which are listed on the Nasdaq stock exchange under the symbol "DBVT," rose $1.26, or 5.8 percent, to close at $22.90.

PROTEON THERAPEUTICS INC.

Continue Reading Below

The company, based in Waltham, Massachussetts, develops drugs for patients with kidney and vascular diseases. It raised $61.1 million after offering 6.1 million shares at $10 per share. Proteon says it will use the cash raised for clinical trials of its drugs. Its stock, which is listed on the Nasdaq stock market under the symbol "PRTO," rose 3 cents to $10.03.

ANCHOR BANCORP WISCONSIN INC.

Anchor BanCorp is the parent company of AnchorBank, which has 54 branches in Wisconsin. It raised $9.7 million after offering about 370,000 shares at $26 per share. The company, headquartered in Madison, Wisconsin, is using the money raised for general corporate uses. The stock is trading on the Nasdaq stock exchange under the symbol "ABCW." Its shares rose $4.32, or 17 percent, to $30.32.